About Fiagon Exit

Fiagon develops a new medical navigation system for intraoperative process control and positioning of instruments for ENT, head-/ neck- and neurosurgery.

htgf-fiagon-applications

Press releases

Press
15. September 2020

Successful Exit for High-Tech Gründerfonds – Intersect ENT acquires Fiagon

Buyer is the Intersect ENT, a medical technology company based in the USThe startup Fiagon AG Medical Technologies expands Intersects portfolio of ENT product offeringsFor the HTGF it is the 8th successful exit during the Corona crisis The High-Tech Gründerfonds sold its shares in Fiagon. The seed investor has accompanied the company for 11 years. The publicly traded company Intersect ENT (NASDAQ: XENT), Menlo Park, California, USA, is dedicated to transforming  the treatment of ear
 
Press
2. June 2014

The HTGF-portfolio company FIAGON AG SECURES A PATENT LICENSE AGREEMENT WITH GE HEALTHCARE, AND FIAGON AG HAS RECEIVED NOTICE OF 510(k) CLEARANCE FROM THE FDA as well as chinese CFDA approval

GE Healthcare and Fiagon AG Announce a Patent License Agreement Fiagon AG today announced that it has entered into an agreement with GE Healthcare. Under the terms of the agreement, Fiagon will acquire a patent license to several of GE Healthcare’s ENT and Cranial navigation technologies. This will help Fiagon surround and back up the 35 issued patents and substantial intellectual property of Fiagon, resulting in greater protection from competitive interference by other companies. This ag
 

Info & Contact

Timo Krüger
Web:
www.fiagon.com

Address

Neuendorfstraße 23b
16761 Henningsdorf

In portfolio

15. Jun 2009 – 12. Sep 2020
Exit